Clinical trial registry record

LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Active Not Recruiting.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated July 1, 2025.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT06198413
Last registry update
July 1, 2025
Status
Active Not Recruiting
Phase
Phase 1
Sponsor
Innostellar Biotherapeutics Co.,Ltd
Enrollment
12
Countries
China
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
12
Population
ALL · 50 Years
Duration
2023-02-27 to 2029-01-01
Intervention
LX102 subretinal injection
Comparator
Not reported
Outcomes measured
Incidence of dose-limiting toxicity (DLT) — 4 weeks; Incidence of adverse events (AEs) and serious adverse events (SAEs) — 52 weeks; Mean change in BCVA from Baseline — 12 weeks, 36 weeks 52 weeks; Mean change in Central Subfield Thickness (CST) from Baseline — 12 weeks, 36 weeks 52 weeks; Mean time from LX102 administration to anti-VEGF rescue injection for the first time — 52 weeks; Percentage of participants requiring anti-VEGF rescue injection — 52 weeks; Mean number of anti-VEGF rescue injections — 52 weeks
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON